Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 1445-1453, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (15)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oda, H.
Right arrow Articles by Urade, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oda, H.
Right arrow Articles by Urade, Y.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2002;48:1445-1453.)
© 2002 American Association for Clinical Chemistry, Inc.

Development and Evaluation of a Practical ELISA for Human Urinary Lipocalin-Type Prostaglandin D Synthase

Hiroshi Oda1, Yasuhiko Shiina1, Kousuke Seiki1, Nobuyuki Sato1, Naomi Eguchi2 and Yoshihiro Urade2a

1 Central Research Institute, Maruha Corp., 16-2, Wadai, Tsukuba, Ibaraki 300-4295, Japan.

2 Department of Molecular Behavioral Biology, Osaka Bioscience Institute, 6-2-4 Furuedai, Suita, Osaka 565-0874, Japan.

aAuthor for correspondence. Fax 81-6-6872-2841; e-mail uradey{at}obi.or.jp.

Background: Urinary excretion of lipocalin-type prostaglandin D synthase (L-PGDS) is significantly increased in patients with chronic renal failure, but its diagnostic potential in less advanced stages of renal diseases remains to be elucidated.

Methods: Six mouse monoclonal antibodies (MAbs) were raised against recombinant human L-PGDS. We constructed a sandwich ELISA with two MAbs that recognized different epitopes with high affinities and assessed its assay performance and clinical utility with urine samples from healthy controls, diabetic patients, and patients with various renal diseases.

Results: Western blot analyses with NH2-terminus-truncated L-PGDS mapped the epitopes to Ala23–Val28 (MAb-7F5 and -10A3), Ser52–Ala73 (MAb-9A6), Tyr107–Val120 (MAb-1B7 and -6F5), and Gly140–Pro155 (MAb-6B9). A sandwich ELISA was constructed with MAb-1B7 and -7F5, the Kd values of which were 3.6 and 3.9 nmol/L, respectively, for native L-PGDS. Recoveries were 91–111%, and intra- and interassay CVs were <6% and <9%, respectively. The ELISA showed parallelism of standard and urine samples and no significant interference by a variety of urinary constituents. Urinary L-PGDS excretion was significantly increased in patients with diabetic nephropathy, IgA nephropathy, and chronic glomerulonephritis even when serum creatinine was not increased. In patients with renal diseases, urinary L-PGDS was correlated with urinary albumin (r = 0.64; P <0.0001), N-acetyl-ß-D-glucosaminidase (r = 0.43; P <0.001), and serum creatinine (r = 0.66; P <0.0001). At a cutoff value of 284 mg/mol creatinine, the assay had sensitivities of 74% for diabetic nephropathy and 83% for chronic glomerulonephritis and a specificity of 93%.

Conclusions: This ELISA system is suitable for measurement of urinary L-PGDS in a routine clinical assay and may be useful to detect less advanced stages of renal diseases.




The following articles in journals at HighWire Press have cited this article:


Home page
 Proc. Natl. Acad. Sci. USAHome page
T. Kanekiyo, T. Ban, K. Aritake, Z.-L. Huang, W.-M. Qu, I. Okazaki, I. Mohri, S. Murayama, K. Ozono, M. Taniike, et al.
Lipocalin-type prostaglandin D synthase/beta-trace is a major amyloid beta-chaperone in human cerebrospinal fluid
PNAS, April 10, 2007; 104(15): 6412 - 6417.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
V. S. Vaidya, V. Ramirez, T. Ichimura, N. A. Bobadilla, and J. V. Bonventre
Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury
Am J Physiol Renal Physiol, February 1, 2006; 290(2): F517 - F529.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Fujimori, K. Kadoyama, and Y. Urade
Protein Kinase C Activates Human Lipocalin-type Prostaglandin D Synthase Gene Expression through De-repression of Notch-HES Signaling and Enhancement of AP-2{beta} Function in Brain-derived TE671 Cells
J. Biol. Chem., May 6, 2005; 280(18): 18452 - 18461.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. M. Hewitt, J. Dear, and R. A. Star
Discovery of Protein Biomarkers for Renal Diseases
J. Am. Soc. Nephrol., July 1, 2004; 15(7): 1677 - 1689.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
S. Herget-Rosenthal, D. Poppen, J. Husing, G. Marggraf, F. Pietruck, H.-G. Jakob, T. Philipp, and A. Kribben
Prognostic Value of Tubular Proteinuria and Enzymuria in Nonoliguric Acute Tubular Necrosis
Clin. Chem., March 1, 2004; 50(3): 552 - 558.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
B. Lumbreras-Lacarra, J. M. Ramos-Rincon, and I. Hernandez-Aguado
Methodology in Diagnostic Laboratory Test Research in Clinical Chemistry and Clinical Chemistry and Laboratory Medicine
Clin. Chem., March 1, 2004; 50(3): 530 - 536.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. Star, T. Hostetter, and G. L. Hortin
New Markers for Kidney Disease
Clin. Chem., September 1, 2002; 48(9): 1375 - 1376.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.